Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
GSK Q4 earnings beat expectations, driven by strong performance of HIV and asthma drugs

GSK Q4 earnings beat expectations, driven by strong performance of HIV and asthma drugs

格隆汇格隆汇2026/02/04 07:18
Show original
Glonghui, February 4th|British pharmaceutical giant GlaxoSmithKline released its financial report on Wednesday, showing that thanks to the strong performance of its HIV and asthma drugs, the company's fourth-quarter profits exceeded expectations. The UK-based pharmaceutical company stated that adjusted earnings per share, excluding certain items, were 25.5 pence, higher than analysts' expectations. The company expects profit growth this year to be between 7% and 9%. Previously, some analysts had forecast earnings per share growth guidance of around 6% to 8%. Newly appointed CEO Luke Miels has set a highly ambitious target that is likely to be surpassed, and sales of the cancer drug Blenrep are also expected to boost revenue this year.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

While the industry faces turmoil, "Nvidia-backed" Nscale presses ahead for NYSE listing! New IPO prospectus reveals 1,344% surge in revenue but a quarterly net loss of $1.69 billion

Nscale, a "New Cloud" provider backed by Nvidia, submitted its latest filing for an initial public offering (IPO) in the United States on Thursday.

智通财经•2026/11/13 00:41

AI capital expenditures peak as global stock market profits"shift gears"! Goldman Sachs outlines three major themes for 2027

Goldman Sachs Portfolio Strategy Research Department pointed out that as the artificial intelligence investment boom peaks, global stock market earnings growth is expected to decline by more than half in 2027. However, recent valuation declines have created attractive entry points for long-duration technology growth stocks.

智通财经•2026/11/13 00:37

Nvidia (NVDA.US) CEO resigns, causing U.S. stocks to fall; Dow Jones drops 189 points

The resignation of Nvidia CEO Jensen Huang has triggered management turmoil, coupled with espionage rumors, leading to a broad decline in the New York stock market on the 12th. The Dow Jones Industrial Average closed down 189.40 points, with the S&P 500 and the Nasdaq Composite also posting losses, and small and mid-cap stocks experiencing the largest declines. Although the long-term outlook for AI remains unchanged, individual corporate governance risks are significantly weighing on the sentiment of the technology sector, driving funds to shift toward competitors and non-tech blue-chip stocks.

智通财经•2026/11/13 00:37